|
Dr. Mazar received his Ph.D. in Biochemistry from the University of Illinois College of Medicine. He is a veteran of drug discovery and development efforts and is internationally recognized for his basic research work on the role of the urokinase plasminogen activator (uPA) system in tumor progression and angiogenesis. At Attenuon, he has led the development of two drugs through phase II trials in cancer and a third drug into pre-clinical development. Previously, Dr. Mazar established and directed all facets of pre-clinical research for Ångstrom Pharmaceuticals, Inc., where he was Vice President, Biology. He is the inventor of both the anti-angiogenic peptide Å6, currently being evaluated in phase II trials in oncology, and a novel uPA receptor-targeting peptide that was licensed to Diatide/Schering AG. Prior to Ångstrom, Dr. Mazar spent over seven years at Abbott Laboratories, where he initiated two anti-angiogenesis pilot projects and was involved in the pre-clinical development of two biologic agents that went through Phase III trials. Dr. Mazar has been a Co-Chair for the subcommittee on Tumor Metastasis, Invasion, and Progression for the American Association for Cancer Research Annual Meeting and a member of the scientific organizing committee for the 2006 International Society for Fibrinolysis and Proteolysis and is a frequent member of NIH study sections. He is also the co-inventor on eight issued patents, thirty one pending patent applications, sixty nine full publications in refereed scientific journals and four book chapters including reviews on the uPA system, mouse tumor models and the therapeutic targeting of integrins. | 